The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Biogen Inc. and Denali Therapeutics Inc. have announced the discontinuation of their experimental Parkinson's disease drug, BIIB122. The decision follows disappointing results from the Phase 2b LUMA study, which failed to meet its primary endpoint of slowing disease progression compared to a placebo. While the drug demonstrated the expected levels of kinase inhibition and maintained safety profiles, it did not achieve the clinical efficacy required to proceed.
Sign in to access this content
Sign InThis clinical failure represents a significant setback in the biotech sector, as Parkinson's remains one of the most difficult indications to treat. Compared to peers like Eli Lilly and AbbVie, which are also investing heavily in neurodegenerative research, this outcome highlights the high risk of drug development in this space, per market data. Biogen has been under pressure to bolster its pipeline as it faces declining revenue from older core products.
Investors are currently monitoring price levels for BIIB and DNLI following the news. Looking ahead at the economic calendar, while there are no sector-specific catalysts in the immediate ±7 day window, broader market sentiment may be influenced by the NY Empire State Manufacturing Index release on May 15, 2026. The focus will now shift to the companies' remaining pipeline assets to gauge long-term recovery prospects.